Efficacy of allogeneic hematopoietic stem cell transplantation in treating post-chronic aplastic anemia induced myelodysplastic syndrome
10.16781/j.CN31-2187/R.20230263
- VernacularTitle:异基因造血干细胞移植治疗继发于慢性再生障碍性贫血的骨髓增生异常综合征的疗效分析
- Author:
Yue SHI
1
;
Yanhong YAO
;
Jingjing YAO
;
Zhibin LIU
;
Lirui ZHANG
;
Feng GAO
;
Xiaoyu LI
;
Shuqing FENG
Author Information
1. 华北理工大学附属医院血液科,唐山 063000;唐山职业技术学院医学系,唐山 063000
- Keywords:
allogeneic hematopoietic stem cell transplantation;
chronic aplastic anemia;
myelodysplastic syndrome;
survival rate
- From:
Academic Journal of Naval Medical University
2025;46(9):1229-1234
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacies of allogeneic hematopoietic stem cell transplantation(allo-HSCT)in the treatment of post-chronic aplastic anemia(CAA)myelodysplastic syndrome(MDS)and primary MDS.Methods A retrospective analysis was conducted on 32 patients who received allo-HSCT treatment in Department of Hematology,North China University of Science and Technology Affiliated Hospital between Feb.2012 and Feb.2022,including 12 patients with post-CAA MDS and 20 patients with primary MDS.The overall survival rate,cumulative incidence of relapse(CIR)rate,non-relapse mortality(NRM)rate,and event-free survival rate were compared between the 2 groups.Results The median follow-up time for CAA to progress to MDS was 120(72-180)months.All the patients were followed up for 36(3-79)months after allo-HSCT.The 3-year overall survival rate of the post-CAA MDS group was significantly higher than that of the primary MDS group(83.8%vs 45.0%,P=0.035).The 3-year CIR of the post-CAA MDS group was significantly lower than that of the primary MDS group(16.7%vs 55.0%,P=0.021).There was no significant difference in the event-free survival rates or NRM rates between the 2 groups(both P＞0.05).Conclusion The post-CAA MDS patients have better survival after allo-HSCT than the primary MDS patients.Early allo-HSCT treatment may improve the prognosis.
